Skip to main content
Radcliffe Medical Education
Medical education learning resources for healthcare professionals
Radcliffe Medical Education banner
Radcliffe Medical Education banner
  • Home
  •  Revolutionising Thrombosis Treatment in ACS, SSP and AF: Bridging the Gaps With Next Generation Anticoagulation Strategies

Revolutionising Thrombosis Treatment in ACS, SSP and AF: Bridging the Gaps With Next Generation Anticoagulation Strategies

Topic:
  • Guidelines
  • Heart Rhythm
  • MI/ACS
  • Optimising treatment
  • Prevention
  • Vascular

Available Credit:

  • 1.00 EBAC

Course Published On:

Course Expiry Date:

Revolutionising Thrombosis Treatment in ACS, SSP and AF
No ratings

Overview

This online CME activity, originally presented at the ESC Congress 2025, explores the latest challenges and developments in stroke prevention for patients with atrial fibrillation (AF) and after acute coronary syndrome (ACS).

 

Led by expert faculty Prof Carolyn Lam (Singapore, UK), Prof Davide Capodanno (Catania, IT), Dr Sneha Shah Jain (Stanford, US) and Prof Jeffrey Weitz (Hamilton, CA), the course provides a concise yet in-depth review of current treatment guidelines, factor XI and innovations in antithrombotics and discussion on how clinical trial evidence may shape practice.

 

The session features an engaging expert discussion alongside a real-world patient case, designed to highlight clinical decision-making in complex scenarios. By the end of the activity, learners will be better equipped to evaluate and apply evidence-based strategies for optimising antithrombotic therapy in this high-risk patient group.

Support Statement

This satellite symposium is supported by an unrestricted educational grant from Bristol Myers Squibb and its Alliance partner Janssen Pharmaceuticals, Inc.

Disclosure

In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.  

 

The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.  

Terms & Conditions

Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable. 

 

The session, ‘Revolutionising Thrombosis Treatment in ACS, SSP and AF: Bridging the Gaps With Next Generation Anticoagulation Strategies’ is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit. 

 

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS). 

 

Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. 

Instruction to Participants

There is no fee for taking part in this online learning activity. 

 

Activities are designed to be completed within 60 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame. 

 

To complete the course and claim certification participants must: 

 

  • Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions
  • Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion

Target Audience

  • Cardiologists
  • Interventional Cardiologists
  • Electrophysiologists
  • Cardiac Surgeons
  • Primary Care Practitioners
  • HCPs involved in the care of ACS, AF and SSP

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Discuss the unmet needs in thrombosis management, MACE burden after ACS, stroke in AF and secondary stroke prevalence and consequences
  • Evaluate the current standard of care for the treatment of ACS, SSP and AF and its limitations
  • Review guidelines and critique current prescribing practices and the implications of inadequate treatment
  • Explain the different strategies for targeting FXI and how FXI inhibition mechanisms differentiate from traditional anticoagulation therapies
  • Identify emerging anticoagulant strategies and describe the efficacy and safety data from Phase 2 FXI inhibitor clinical trials as well as ongoing Phase 3 trials and potential place in therapy for ACS, AF and SSP
  • Apply evidence-based anticoagulation strategies by optimising treatment decisions and addressing patient-specific risk factors

Module

Title

Duration

Speakers

Part 1 Welcome 3m 7s Carolyn Lam
Part 2 Stroke Prevention in AF and MACE after ACS: Prevalence and Challenges 9m 47s Davide Capodanno
Part 3 Current Treatments in AF and ACS, Safety and Guidelines 10m 6s Sneha Jain
Part 4 Targeting Factor XI: Innovations in Anticoagulation 8m 38s Jeffrey Weitz
Part 5 Shaping Clinical Practice and Clinical Trials 13m 2s Carolyn Lam
Part 6 Audience Q&A and Closing Remarks 4m 18s Carolyn Lam Davide Capodanno Sneha Jain Jeffrey Weitz
Part 1.

Welcome

Duration: 3m 7s

Speakers: Carolyn Lam

Part 2.

Stroke Prevention in AF and MACE after ACS: Prevalence and Challenges

Duration: 9m 47s

Speakers: Davide Capodanno

Part 3.

Current Treatments in AF and ACS, Safety and Guidelines

Duration: 10m 6s

Speakers: Sneha Jain

Part 4.

Targeting Factor XI: Innovations in Anticoagulation

Duration: 8m 38s

Speakers: Jeffrey Weitz

Part 5.

Shaping Clinical Practice and Clinical Trials

Duration: 13m 2s

Speakers: Carolyn Lam

Part 6.

Audience Q&A and Closing Remarks

Duration: 4m 18s

Speakers: Carolyn Lam Davide Capodanno Sneha Jain Jeffrey Weitz

Chair

Carolyn Lam

Carolyn Lam

National Heart Centre Singapore Duke-NUS, Singapore, SG

Prof Carolyn Lam is a Senior Consultant Cardiologist and Director of Women’s Heart Health at the National Heart Centre Singapore, where she pioneered the country’s first Women’s Heart Clinic.

View full profile

Speaker

Davide Capodanno

Davide Capodanno

University of Catania, Catania, IT

Prof Davide Capodanno is Professor of Cardiology at the University of Catania and Interventional Cardiologist at the Azienda Ospedaliero Universitaria “Policlinico G. Rodolico-S. Marco”, Catania, IT.

View full profile
Sneha Shah Jain

Sneha Jain

Stanford Health Care, Stanford, US

Dr Sneha Shah Jain is Clinical Assistant Professor of Medicine and Director of the GUIDE-AI Lab at Stanford Health Care, US.

View full profile
Jeffrey Weitz

Jeffrey Weitz

Thrombosis and Atherosclerosis Research Institute (TaARI), Hamilton, CA

Prof Jeffrey I Weitz is Professor of Medicine and Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis & Atherosclerosis Research Institute (TaARI), Hamilton, CA.

View full profile
1.00 EBAC

Revolutionising Thrombosis Treatment in ACS, SSP and AF: Bridging the Gaps With Next Generation Anticoagulation Strategies' programme has been accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 CME point, equating to 1 hour of learning. Physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™.

Related Courses

Translating Aortic Stenosis Guidelines Into Practice: Evidence-Based Decisions for the Heart Team
  • 1.00 EBAC

Learning objectives

  • Recall recent guideline recommendations for the management of aortic stenosis
  • Summarise the evidence supporting TAVI across the sub-groups of aortic stenosis, age and surgical risk
  • Develop an expert guided approach to patient selection and referral for TAVI
  • Adopt an evidence-based approach for the lifetime management of younger patients with aortic stenosis
See more
Managing Hypertension in CVD: How Low Can We Go?
  • 1.00 EBAC

Learning objectives

  • Describe the link between CVD and hypertension
  • Classify hypertension patients according to their cardiovascular risk
  • Recall recent guideline-directed and evidence-based strategies for managing very high CVD risk patients
  • Apply guideline-directed and evidence-based management strategies to a case study
  • Use expert guidance to adopt optimal multidisciplinary antihypertensive management strategies in patients with very high cardiovascular risk
See more
Advancing Patient Care in Hypertrophic Cardiomyopathy
  • 0.50 AMA PRA Credit

Learning objectives

  • Recall recent trial data for novel disease modifying therapy in HCM
  • Describe the evolving guideline directed approach to managing HCM
  • Develop an expert-led approach to implementing novel therapy in clinical practice
See more